Corrigendum

REPORT ON EVALUATION OF PROJECTS FOR THE CONVERSION OF CFC-BASED METERED DOSE INHALERS TO CFC-FREE TECHNOLOGIES

This document is issued to:

- Replace paragraph 48 as follows:

48. Argentina requested and obtained approval for CFC essential use exemptions only in 2010 and 2011 for 178 ODP tonnes and 107.2 ODP tonnes respectively at the Twenty-first and Twenty-second meetings of the Parties although the original project foresaw the request of essential-use exemption until 2014.

- Replace paragraph 56 as follows:

56. In Argentina, Laboratorio Pablo Cassará (LPC) developed the isobutane-based technology internally and therefore own the intellectual property rights to their own formulations. The molecules produced at LPC are: salbutamol, budesonide, ipratropium, salbutamol/beclomethasone, fluticasone/salmeterol, salbutamol/ipratropium and budesonide/salmeterol. The molecules produced at Denver Pharma (DF) are budesonide, beclomethasone, salbutamol, salmeterol/fluticasone and salmeterol/beclomethasone. The selection of the molecules responded to the needs of the market and the corresponding market shares and niches of each of the enterprises. The selection of the MDI as the delivery method followed a careful analysis of all available alternatives. LPC undertook two conversions at once, namely the conversion of the existing production lines to HFA-based MDIs and the design and installation of a new production line for isobutane-based MDIs. The latter followed internationally recognized standards for manufacturing plant project development.